Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERLOT study of milk and antacid effects on erlotinib absorption
NL-OMON43280Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of erlotinib in bronchial carcinoma and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Erasmus MC. Started Feb 2017; status: active, not recruiting.
02
Drugs
erlotinib
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON43280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43280.